Adage Capital Partners GP L.L.C. Makes New Investment in Takeda Pharmaceutical Co. $TAK

Key Points

• Adage Capital Partners GP L.L.C. has invested approximately $51.05 million in Takeda Pharmaceutical Co., acquiring 3,433,023 shares, which represents about 0.11% ownership.
• Several institutional investors have also increased their positions in Takeda, notably BNP Paribas Financial Markets, which raised its stake by 15,449.0% in the fourth quarter.
• Recent analyst ratings for Takeda have been mixed, with Zacks Research downgrading it from a "hold" to a "strong sell," although the stock has a current consensus rating of "Hold."

Adage Capital Partners GP L.L.C. bought a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,433,023 shares of the company's stock, valued at approximately $51,049,000. Adage Capital Partners GP L.L.C. owned approximately 0.11% of Takeda Pharmaceutical at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its holdings in Takeda Pharmaceutical by 11.0% during the first quarter. Royal Bank of Canada now owns 441,054 shares of the company's stock worth $6,558,000 after buying an additional 43,706 shares in the last quarter. Graham Capital Management L.P. bought a new stake in Takeda Pharmaceutical during the first quarter worth approximately $2,361,000. Nomura Holdings Inc. bought a new stake in Takeda Pharmaceutical during the first quarter worth approximately $338,000. Baird Financial Group Inc. bought a new stake in Takeda Pharmaceutical during the first quarter worth approximately $276,000. Finally, Vident Advisory LLC boosted its holdings in Takeda Pharmaceutical by 52.4% during the first quarter. Vident Advisory LLC now owns 20,732 shares of the company's stock worth $308,000 after buying an additional 7,126 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Trading Up 0.7%

Shares of TAK stock traded up $0.11 during trading hours on Friday, reaching $15.40. 3,326,096 shares of the stock traded hands, compared to its average volume of 2,709,035. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $15.56. The business has a fifty day moving average price of $14.83 and a 200 day moving average price of $14.78. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $48.99 billion, a PE ratio of 10.00 and a beta of 0.22.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, equities research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a report on Thursday, August 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold".

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.